GondolaBio, LLC
Head of Oligonucleotide Therapeutics
GondolaBio, LLC, Palo Alto, California, United States, 94306
All Jobs > VP Oligonucleotide Therapeutics
San Francisco • Research and Translational Science
Full-time
Description VP Oligonucleotide Therapeutics About GondolaBio GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting‑edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
Who You Are You are an accomplished leader in oligonucleotide drug discovery and development, with a strong track record of advancing oligonucleotides (conjugated and unconjugated) from concept through development candidate (DC) nomination and into IND. You bring deep expertise in assay development, oligo design, and translational research, and you thrive in owning programs end-to-end. While hands‑on when needed, you excel at setting scientific vision, leading cross‑functional execution, and ensuring rigorous decision‑making in a lean, high‑impact environment.
Key Responsibilities
Program ownership: Serve as program owner for oligonucleotide discovery and development programs, driving them from target validation through DC nomination and IND submission.
Oligo design and development: Lead the strategy and execution for antisense oligonucleotides and siRNAs, with a particular emphasis on conjugated oligos (e.g., GalNAc, peptide, antibody, or other ligand‑based conjugates).
Assay development: Establish and oversee cellular and biochemical assays to evaluate oligo potency, specificity, uptake, trafficking, and mechanism of action. Ensure assay platforms are robust, scalable, and reproducible.
Conjugation biology: Partner closely with chemistry and delivery teams to design and optimize conjugated oligos; directly contribute to design hypotheses and screen conjugates in relevant cellular and in‑vivo models.
Development candidate nomination: Drive scientific packages and cross‑functional decision‑making to select and nominate oligo development candidates for IND‑enabling studies.
IND‑enabling leadership: Guide IND‑enabling biology and translational strategy, integrating preclinical data, biomarkers, and mechanistic insights into regulatory filings.
Translational strategy: Build and apply translational models that connect preclinical findings with human biology. Develop and integrate biomarker strategies to guide dose selection, patient stratification, and early clinical readouts.
Cross‑functional leadership: Lead and inspire cross‑functional program teams, ensuring alignment across biology, chemistry, DMPK, CMC, toxicology, and clinical groups to deliver on program objectives.
External collaboration: Evaluate and manage CROs and academic partnerships to accelerate program timelines while ensuring scientific rigor and data quality.
Regulatory support: Provide biological and translational expertise to regulatory documents, including IND packages, Investigator’s Brochures, and briefing books.
Preferred Education & Experience
Ph.D. in molecular biology, pharmacology, or related field, or equivalent advanced degree.
12+ years of experience in oligonucleotide drug discovery and development, with at least 5 years in a leadership role.
Strong track record of nominating oligonucleotide development candidates and driving programs into IND.
Expertise in assay development, in‑vitro and in‑vivo pharmacology, and translational/biomarker strategy.
Demonstrated ability to lead cross‑functional programs through IND‑enabling studies.
Regulatory‑facing experience strongly preferred.
Nice‑to‑Haves
Experience spanning both antisense and siRNA modalities.
Exposure to multiple conjugation approaches (GalNAc, peptides, antibodies, lipids).
Direct experience building translational packages and biomarker plans for early‑phase.
Proven ability to scale teams and capabilities in a fast‑paced biotech environment.
Core Values
Patient Champions, who put patients first and uphold strict ethical standards.
Entrepreneurial Operators, who drive toward practical solutions and have an ownership mindset.
Truth Seekers, who are detailed, rational, and humble problem solvers.
Individuals Who Inspire Excellence in themselves and those around them.
High‑quality executors, who execute against goals and milestones with quality, precision, and speed.
What We Offer
Patient Days, where we are fortunate to hear directly from individuals living with the conditions we are seeking to impact throughout the year and learn how we can improve our efforts.
A culture inspired by our values: put patients first, think independently, be radically transparent, every minute counts, and let the science speak.
An unyielding commitment to always putting patients first.
A de‑centralized model that enables our program teams to focus on advancing science and helping patients. Our affiliate structure is designed to eliminate bureaucracy and put decision‑making power in the hands of those closest to the science.
A place where you own the vision – both for your program and your own career path.
A collaborative, fast‑paced, data‑driven environment where we inspire ourselves and each other to always perform at the top of our game.
Access to learning and development resources to help you get in the best professional shape of your life.
Robust and market‑competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs).
Rapid career advancement for strong performers.
Potential ability to work on multiple GondolaBio Pharma programs across multiple therapeutic areas over time.
Partnerships with leading institutions.
Commitment to Diversity, Equity & Inclusion.
The base pay range for this position is $290,000 to $340,000 per year. The actual compensation offered will be determined based on a number of job‑related factors, including experience, skills, qualifications, and location. A bonus plan and equity will also be offered.
#J-18808-Ljbffr
San Francisco • Research and Translational Science
Full-time
Description VP Oligonucleotide Therapeutics About GondolaBio GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting‑edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
Who You Are You are an accomplished leader in oligonucleotide drug discovery and development, with a strong track record of advancing oligonucleotides (conjugated and unconjugated) from concept through development candidate (DC) nomination and into IND. You bring deep expertise in assay development, oligo design, and translational research, and you thrive in owning programs end-to-end. While hands‑on when needed, you excel at setting scientific vision, leading cross‑functional execution, and ensuring rigorous decision‑making in a lean, high‑impact environment.
Key Responsibilities
Program ownership: Serve as program owner for oligonucleotide discovery and development programs, driving them from target validation through DC nomination and IND submission.
Oligo design and development: Lead the strategy and execution for antisense oligonucleotides and siRNAs, with a particular emphasis on conjugated oligos (e.g., GalNAc, peptide, antibody, or other ligand‑based conjugates).
Assay development: Establish and oversee cellular and biochemical assays to evaluate oligo potency, specificity, uptake, trafficking, and mechanism of action. Ensure assay platforms are robust, scalable, and reproducible.
Conjugation biology: Partner closely with chemistry and delivery teams to design and optimize conjugated oligos; directly contribute to design hypotheses and screen conjugates in relevant cellular and in‑vivo models.
Development candidate nomination: Drive scientific packages and cross‑functional decision‑making to select and nominate oligo development candidates for IND‑enabling studies.
IND‑enabling leadership: Guide IND‑enabling biology and translational strategy, integrating preclinical data, biomarkers, and mechanistic insights into regulatory filings.
Translational strategy: Build and apply translational models that connect preclinical findings with human biology. Develop and integrate biomarker strategies to guide dose selection, patient stratification, and early clinical readouts.
Cross‑functional leadership: Lead and inspire cross‑functional program teams, ensuring alignment across biology, chemistry, DMPK, CMC, toxicology, and clinical groups to deliver on program objectives.
External collaboration: Evaluate and manage CROs and academic partnerships to accelerate program timelines while ensuring scientific rigor and data quality.
Regulatory support: Provide biological and translational expertise to regulatory documents, including IND packages, Investigator’s Brochures, and briefing books.
Preferred Education & Experience
Ph.D. in molecular biology, pharmacology, or related field, or equivalent advanced degree.
12+ years of experience in oligonucleotide drug discovery and development, with at least 5 years in a leadership role.
Strong track record of nominating oligonucleotide development candidates and driving programs into IND.
Expertise in assay development, in‑vitro and in‑vivo pharmacology, and translational/biomarker strategy.
Demonstrated ability to lead cross‑functional programs through IND‑enabling studies.
Regulatory‑facing experience strongly preferred.
Nice‑to‑Haves
Experience spanning both antisense and siRNA modalities.
Exposure to multiple conjugation approaches (GalNAc, peptides, antibodies, lipids).
Direct experience building translational packages and biomarker plans for early‑phase.
Proven ability to scale teams and capabilities in a fast‑paced biotech environment.
Core Values
Patient Champions, who put patients first and uphold strict ethical standards.
Entrepreneurial Operators, who drive toward practical solutions and have an ownership mindset.
Truth Seekers, who are detailed, rational, and humble problem solvers.
Individuals Who Inspire Excellence in themselves and those around them.
High‑quality executors, who execute against goals and milestones with quality, precision, and speed.
What We Offer
Patient Days, where we are fortunate to hear directly from individuals living with the conditions we are seeking to impact throughout the year and learn how we can improve our efforts.
A culture inspired by our values: put patients first, think independently, be radically transparent, every minute counts, and let the science speak.
An unyielding commitment to always putting patients first.
A de‑centralized model that enables our program teams to focus on advancing science and helping patients. Our affiliate structure is designed to eliminate bureaucracy and put decision‑making power in the hands of those closest to the science.
A place where you own the vision – both for your program and your own career path.
A collaborative, fast‑paced, data‑driven environment where we inspire ourselves and each other to always perform at the top of our game.
Access to learning and development resources to help you get in the best professional shape of your life.
Robust and market‑competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs).
Rapid career advancement for strong performers.
Potential ability to work on multiple GondolaBio Pharma programs across multiple therapeutic areas over time.
Partnerships with leading institutions.
Commitment to Diversity, Equity & Inclusion.
The base pay range for this position is $290,000 to $340,000 per year. The actual compensation offered will be determined based on a number of job‑related factors, including experience, skills, qualifications, and location. A bonus plan and equity will also be offered.
#J-18808-Ljbffr